文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

危重症患者无创电磁膈神经刺激:可行性研究

Noninvasive Electromagnetic Phrenic Nerve Stimulation in Critically Ill Patients: A Feasibility Study.
PubMed 文献 · Chest · 2024-02-24
一句话结论在ICU机械通气患者中,双侧经皮无创电磁膈神经刺激可行,中位23秒找到最佳刺激位置,并可能防止膈肌变薄。

这项可行性非随机对照研究旨在纳入插管36小时内且预计机械通气≥72小时的危重症患者,干预组接受每次15分钟、每日两次的双侧经皮无创电磁膈神经刺激,对照组接受标准治疗。因欧盟法规修订要求医疗器械重新审批,研究提前终止,仅纳入11例患者(干预组5例,对照组6例)。找到合适刺激位置的中位时间为23秒(四分位距12-62秒);仅刺激即可达到3-6 mL/kg理想体重的通气在1701次刺激中占732次(43.0%),加用压力支持后在4036次刺激中占2511次(62.2%)。双侧无创电磁膈神经刺激防止了膈肌厚度下降(P = .034)直至第10天。作者认为该技术在ICU可行,可能有益于防止机械通气期间的膈肌萎缩,但通气有效性需进一步评估。

要点

  • 在ICU危重症机械通气患者中,双侧经皮无创电磁膈神经刺激可行,找到合适刺激位置的中位时间为23秒(四分位距12-62秒)。
  • 干预方案为每次15分钟、每日两次的双侧经皮无创电磁膈神经刺激,87%的患者完成了每日两次方案,包括次日补做在内为92%。
  • 仅用刺激达到3-6 mL/kg理想体重通气在1701次刺激中占732次(43.0%),加用压力支持后在4036次刺激中占2511次(62.2%)。
  • 双侧无创电磁膈神经刺激防止了膈肌厚度下降(P = .034)直至第10天。
  • 研究因欧盟法规修订要求医疗器械重新审批而提前终止,仅纳入11例患者(干预组5例,对照组6例),通气有效性需进一步评估。

适用人群与场景

  • 插管36小时内且预计机械通气≥72小时的危重症患者。

处置流程与药物剂量

  • 干预组接受每次15分钟、每日两次的双侧经皮无创电磁膈神经刺激,对照组接受标准治疗。
  • 若刺激强度足够,则在不加压力支持下用无创电磁膈神经刺激进行通气;若必要,加用压力支持以充分通气。

研究设计与关键结果

  • 研究类型为可行性非随机对照研究,因欧盟法规修订要求医疗器械重新审批而提前终止,共纳入11例患者(干预组5例,对照组6例)。
  • 找到合适刺激位置的中位时间为23秒(四分位距12-62秒)。
  • 每日两次干预方案在87%的患者中执行,包括次日补做在内为92%。
  • 仅用刺激达到3-6 mL/kg理想体重通气在1701次刺激中占732次(43.0%),加用压力支持后在4036次刺激中占2511次(62.2%)。
  • 双侧无创电磁膈神经刺激防止了膈肌厚度下降(P = .034)直至第10天。

证据类型、等级与局限

  • 证据类型:可行性非随机对照研究。
  • 局限:研究因欧盟法规修订要求医疗器械重新审批而提前终止,仅纳入11例患者(干预组5例,对照组6例);作者指出无创电磁膈神经刺激的通气有效性需进一步评估。

对床旁实践的改变

  • 作者认为,双侧经皮无创电磁膈神经刺激在ICU环境中可行,并具有防止机械通气期间膈肌萎缩的潜在益处。
  • 作者指出,无创电磁膈神经刺激的通气有效性需进一步评估。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Electromagnetic stimulation of the phrenic nerve induces diaphragm contractions, but no coils for clinical use have been available. We recently demonstrated the feasibility of ventilation using bilateral transcutaneous noninvasive electromagnetic phrenic nerve stimulation (NEPNS) before surgery in lung-healthy patients with healthy weight in a dose-dependent manner.

RESEARCH QUESTION: Is NEPNS feasible in critically ill patients in an ICU setting?

STUDY DESIGN AND METHODS: This feasibility nonrandomized controlled study aimed to enroll patients within 36 h of intubation who were expected to remain ventilated for ≥ 72 h. The intervention group received 15-min bilateral transcutaneous NEPNS bid, whereas the control group received standard care. If sufficient, NEPNS was used without pressure support to ventilate the patient; pressure support was added if necessary to ventilate the patient adequately. The primary outcome was feasibility, measured as time to find the optimal stimulation position. Further end points were sessions performed according to the protocol or allowing a next-day catch-up session and tidal volume achieved with stimulation reaching only 3 to 6 mL/kg ideal body weight (IBW). A secondary end point was expiratory diaphragm thickness measured with ultrasound from days 1 to 10 (or extubation).

RESULTS: The revised European Union regulation mandated reapproval of medical devices, prematurely halting the study. Eleven patients (five in the intervention group, six in the control group) were enrolled. The median time to find an adequate stimulation position was 23 s (interquartile range, 12-62 s). The intervention bid was executed in 87% of patients, and 92% of patients including a next-day catch-up session. Ventilation with 3 to 6 mL/kg IBW was achieved in 732 of 1,701 stimulations (43.0%) with stimulation only and in 2,511 of 4,036 stimulations (62.2%) with additional pressure support. A decrease in diaphragm thickness was prevented by bilateral NEPNS (P = .034) until day 10.

INTERPRETATION: Bilateral transcutaneous NEPNS was feasible in the ICU setting with the potential benefit of preventing diaphragm atrophy during mechanical ventilation. NEPNS ventilation effectiveness needs further assessment.

TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT05238753; URL: www.

CLINICALTRIALS: gov.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Panelli A, Grimm AM, Krause S, et al. Noninvasive Electromagnetic Phrenic Nerve Stimulation in Critically Ill Patients: A Feasibility Study. Chest. 2024. PMID: 38403186. doi:10.1016/j.chest.2024.02.035

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。